Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Copper Miners ETF (COPX) vs Viatris Inc (VTRS) Price & Performance

Global X Copper Miners ETFTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Global X Copper Miners ETF vs Viatris Inc — how do they compare? Global X Copper Miners ETF trades at $84.47 (market cap $7.37B), while Viatris Inc trades at $17.4 (market cap $20.12B). The key difference: Viatris Inc is far larger — about 2.7× Global X Copper Miners ETF's market cap, and Viatris Inc pays a 2.74% dividend while Global X Copper Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 50 Days and Viatris Inc for 57 Days on average.

COPXVTRS
Market Cap
$7.37B$20.12B
Volume
1,988,5327,543,511
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$96.45$18.27
52-Week Low
$57.43$9.74
Typical Hold Time
50 Days57 Days
Enterprise Value
—$32.24B
Dividend Yield
—2.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Copper Miners ETF

COPX (Global X Copper Miners ETF) is trading at $83.58, down 3.13% with a bearish technical signal. The ETF faces selling pressure with 15 sell signals versus 2 buy signals across technical indicators. Copper fundamentals remain strong with prices near all-time highs above $6.85 per pound, driven by AI infrastructure demand and supply constraints. Recent news highlights copper's critical role in electrification and AI infrastructure, though technical indicators suggest near-term weakness.

The long-term copper thesis remains compelling due to structural supply deficits and AI-driven demand growth. However, near-term risks include potential Federal Reserve policy impacts and mining equity underperformance relative to copper prices. The ETF offers operational leverage to copper prices but faces volatility from global surplus projections and macroeconomic factors.

Viatris Inc

Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.

The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

COPX
100% Buy0% Sell
Avg holding period · 50 Days
VTRS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Global X Copper Miners ETF

COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.

Read more on COPX →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →